Zelda Therapeutics makes significant progress in medicinal cannabis research programs

Zelda Therapeutics makes significant progress in medicinal cannabis research programs

Listed medicinal cannabis company Zelda Therapeutics (ASX: ZLD) has made progress in a number of key research programs during the March 2018 financial quarter.

Zelda recently received approval for a major study into the pharmacology of cannabinoids in the treatment of paediatric autism patients.

The study is set to be conducted at the USA-based Children's Hospital of Philadelphia, and Zelda says it is a key milestone in ongoing medical cannabis research in a clinical environment.

The group has also expanded its pre-clinical pancreatic cancer research programme with Curtin University.

The study focuses on live animal studies to investigate the effect of a range of the group's formulations in combination with existing chemotherapy agents.

Zelda says animal research is a major precursor to future human clinical trials.

During the last quarter, the group announced the initiation of a new pre-clinical research programme exploiting the potential for certain cannabinoids formulations to reduce the impact of diabetes-associated cognitive decline.

This study is also being conducted in partnership with Curtin University.

Zelda says it has made "excellent" progress on its clinical trial that is investigating the effect of medicinal marijuana on people with chronic insomnia symptoms.

Outside of the research and development sphere, Zelda has been approved for trading on the OTCQB Venture Market in the USA under the symbol ZLDAF.

The OTCQB is a US-based trading platform for early-stage and developing USA and international companies.

Through this new market, the group aims to grow its access to the US investment community.

Executive chairman Harry Karelis said he was pleased with Zelda's performance in the March quarter.

"We have made an excellent start to 2018 with significant progress on multiple research fronts autism, pancreatic cancer, insomnia and now cognitive decline," says Karelis.

"We firmly believe our approach is the correct strategy in an environment where regulators continue to tighten their oversight on groups making unsubstantiated claims for cannabinoid products."

Shares in Zelda Therapeutics closed at $0.12 per share on 27 April 2018.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

How to conduct an effective board assessment: a step-by-step guide
Partner Content
Your directors should conduct a board assessment annually. Let's examine what a boa...
OnBoard
Advertisement

Related Stories

Love is in the wallet: Australians to splurge $485m on Valentine’s Day

Love is in the wallet: Australians to splurge $485m on Valentine’s Day

Vibrant bouquets and sweet treats are high on the agenda for Austra...

Creditors vote ‘overwhelmingly’ in favour of Brosa liquidation

Creditors vote ‘overwhelmingly’ in favour of Brosa liquidation

Creditors have ‘overwhelmingly’ voted to wind up c...

Collection House, Wallet Wizard owner Credit Corp shares buoyant on loan book uplift

Collection House, Wallet Wizard owner Credit Corp shares buoyant on loan book uplift

Shares in Credit Corp (ASX: CCP), the owner of Wallet Wizard, ...

Booktopia secures $12 million for Western Sydney distribution centre

Booktopia secures $12 million for Western Sydney distribution centre

Having last week revealed its plans to improve its full year earnin...